rss
Ann Rheum Dis 2008;67:710-712 doi:10.1136/ard.2007.081513
  • Concise report

The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease

  1. E J Cepeda1,
  2. F M Williams1,
  3. M L Ishimori2,
  4. M H Weisman2,
  5. J D Reveille1
  1. 1
    The University of Texas-Houston Health Science Center, Houston, TX, USA
  2. 2
    Cedars-Sinai Medical Center, Los Angeles, CA, USA
  1. John D Reveille, MD, The University of Texas-Houston Health Science Center, MSB 5.270, 6431 Fannin, Houston, TX 77030, USA; john.d.reveille{at}uth.tmc.edu
  • Accepted 22 October 2007
  • Published Online First 13 December 2007

Abstract

Objective: The purpose of this study was to examine the safety and efficacy of anti-tumour necrosis factor (TNF) agents (etanercept, infliximab and adalimumab) in HIV-positive patients with rheumatic diseases refractory to standard therapy.

Methods: Patients were treated with anti-TNF blocker with rheumatic diseases refractory to disease modifying antirheumatic drugs who had a CD4 count of >200 mm3 and an HIV viral load of <60 000 copies/mm3 and no active concurrent infections. Changes in CD4 counts, HIV viral loads, or other adverse effects while on anti-TNF agents and clinical response were monitored for 28.1 (SD 20.9) months (range 2.5–55).

Results: Eight HIV-positive patients were treated with anti-TNF blockers (two patients with rheumatoid arthritis, three with psoriatic arthritis, one with undifferentiated spondyloarthritis, one with reactive arthritis and one with ankylosing spondylitis). No significant clinical adverse effect was attributed to this treatment in any patient. CD4 counts and HIV viral load levels remained stable in all patients. Three patients on etanercept therapy and two patients on infliximab had sustained clinical improvement in their rheumatic diseases.

Conclusions: This retrospective series of eight patients suggests that treatment with anti-TNF-α therapy is a viable alternative in HIV patients without advanced disease with associated rheumatic diseases refractory to standard therapy.

Footnotes

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. ard.2007.081513v1
    2. 67/5/710 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.